Vertex Pharma sees 2014 revenues below estimates

Vertex Pharmaceuticals (VRTX -1.6%) is out with financial guidance ahead of its presentation at the JPMorgan Healthcare Conference on Tuesday.

Cash and equivalents as of FY13 end: $1.47B.

FY14 revenues seen at $570-600M versus consensus of $659.93B.

Kalydeco net revenues for FY14 projected at: $470-500M.

2014 projected opex: $900-950M. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs